Leadership Team

Our leadership team is comprised of proven senior executives with extensive commercial, development and acquisition experience in the biopharmaceutical industry.

Board of Directors

The Horizon board is made up of experienced professionals with diverse backgrounds who work closely with our leadership team to help us identify and commercialize novel therapies for patients in areas of high unmet medical need.

Tim joined Horizon Pharma in June 2008 as president and chief executive officer and has served as chairman of our board of directors since 2010. Prior to joining Horizon Pharma plc, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Tim served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Tim served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth.

Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, Pa.. He serves as chairman of the board of Egalet Corporation (NASDAQ: EGLT) and the Illinois Biotechnology Innovation Organization (iBIO) and sits on the board of directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is also a member of the Illinois Innovation Council.

Close Drawer

Bob joined Horizon Pharma in March 2014 as chief business officer. Prior to joining Horizon Pharma, he spent more than 11 years as managing director and head of the life sciences investment banking group at JMP Securities LLC, a full-service investment bank. Prior to JMP, Bob was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He also has held roles at Red Hen Bread, InStadium, Shearson Lehman Hutton and Ernst & Whinney. Bob has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements. He has also served as a financial advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $3 billion.

Bob holds a bachelor’s degree from the University of Notre Dame.

Close Drawer

Paul joined Horizon Pharma in June 2014 as executive vice president, finance and became executive vice president, chief financial officer on Oct. 1, 2014. Prior to joining Horizon Pharma, he served as senior vice president, finance–treasury and corporate development of OfficeMax, Inc., an office supply company, from Aug. 2013 to June 2014, and as vice president, finance–treasury and corporate development from Aug. 2012 to July 2013.

Paul held various financial leadership roles during a 19 year career at Alberto Culver Company, a hair and skin beauty care company, including serving as vice president, finance integration from May 2011 to May 2012 following Unilever’s acquisition of Alberto Culver. Previously, he served as vice president, international finance and treasurer from 2010 to 2011 and vice president, corporate controller from 2004 to 2010. From 1993 to 2004, Paul served in other positions of increasing responsibility at Alberto Culver, including manager, corporate accounting; director, corporate finance; senior director, corporate finance; and corporate controller. He also served in various positions in the audit practice at KPMG LLP from 1986 to 1993.

Paul received his Bachelor of Science in Accountancy from the University of Illinois at Urbana-Champaign and is a certified public accountant.

Close Drawer

Barry joined Horizon Pharma in June 2014 and in his current role is responsible for all business operations and project management, including human resources and information technology. Prior to joining Horizon, he spent more than 25 years as partner and owner of Crystal Clear Communications, a consulting firm focused on working with board of directors, chief executive officers and executive teams to develop and execute their corporate strategies. In addition, Barry assisted building organizational behaviors and competencies needed to drive effective organizations. Barry has worked with Fortune 500 and 1,000 companies such as Abbott, Pepsi Bottling Group, W.W. Grainger, Genentech, Rockwell Automation and Manpower.

Prior to Crystal Clear, Barry was a founder and president of Review Services and Asset Management Group, a licensed investment advisory firm. He serves on the board of Palermo Villa, a private company.

Close Drawer

Brian joined Horizon Pharma in January 2013 and has more than 15 years of experience providing legal and counsel to businesses in the healthcare and life sciences industries. Prior to joining Horizon Pharma, he served as associate general counsel for Fenwal, Inc., a global life sciences manufacturer of products for transfusion medicine. Prior to Fenwal, he was senior counsel, business development, commercial, and research and development, at TAP Pharmaceutical Products and Takeda Pharmaceuticals North America, and also previously served as chief compliance officer at Schwarz Pharma.

Brian is licensed to practice law in the states of Illinois and Indiana. He received his Juris Doctor degree from Indiana University School of Law, his Master of Business Administration from Kellogg School of Management at Northwestern University, and his bachelor’s degree from Purdue University.

Close Drawer

Dr. Sherman joined Horizon Pharma in June 2009 as executive vice president, development and regulatory affairs and chief medical officer. From June 2011 to Sept. 2014, he served as executive vice president, development, manufacturing, and regulatory affairs and chief medical officer. Since then, he has served as executive vice president, research and development and chief medical officer.

From June 2009 to June 2010, Dr. Sherman also served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Dr. Sherman serves as DIA liaison to the Clinical Trial Transformation Initiative (CTTI), a public-private partnership founded by the U.S. Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. He also serves on the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process. He is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine.

From August 2007 to June 2009, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. From June 2007 to Aug. 2007, he served as vice president of clinical science at Takeda Global Research and Development. From Sept. 2000 through June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm, Inc., a biopharmaceutical company.
From October 1992 to Aug. 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle.

Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.

Close Drawer

Mike joined Horizon in October 2016 as part of the Raptor Pharmaceutical Corp. acquisition. He brings more than 37 years of experience in pharmaceutical development and prior to joining Horizon, he served as senior vice president of technical operations at Raptor, where he was responsible for quality, manufacturing, supply chain and pharmaceutical development.  From July 2004 to March 2015, Mike served in various positions including senior vice president of product development at Jazz Pharmaceuticals plc. In addition, he was responsible for manufacturing, supply chain program management, and technical development in addition to leading the chemistry manufacturing and controls (CMC) diligence for Jazz’s acquisitions of Orphan Medical Inc., Azur Pharma Ltd, EUSA Pharma, and Gentium SpA.

Prior to Jazz, Mike served in positions of increasing responsibility at ALZA Corporation. In addition, Mike has led technical development and commercial manufacturing for chemical and pharmaceutical products, which incorporated several drug delivery technologies, including oral, implantable and injection systems. He is an inventor on 28 U.S. patents.

Mike received a Bachelor of Science in Chemical Engineering from the University of California, Berkeley and is a registered Professional Engineer in the State of California.

Close Drawer

Dave joined Horizon Pharma in October 2016 as part of the Raptor Pharmaceutical Corp. acquisition. He has more than 30 years of experience in the healthcare industry, with the last 15 years dedicated to developing and commercializing treatments for rare diseases. Prior to joining us, Dave was chief commercial officer at Raptor, where he led the global commercialization of PROCYSBI® and QUINSAIR®. Prior to Raptor, he held chief commercial and corporate development roles at Allergen Research Corporation, a developer of treatments for food allergies, Dynavax Technologies, a drug development and vaccine company and Aerovance, Inc., a biotechnology company. Dave also held senior-level leadership positions at Dr. Reddy’s Laboratories, Inc., Chiron Corporation, InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI® for cystic fibrosis and ACTIMMUNE® for the treatment of multiple rare diseases.

He received a Bachelor of Arts in Chemistry from Indiana University and a Master of Business Administration in marketing from Indiana State University.

Close Drawer

George joined Horizon Pharma in 2008 as a consultant and transitioned to a full-time employee in April 2015. He currently serves as executive vice president, primary care business unit where he is tasked with leading the forward-looking strategy, as well as establishing operational goals for the team. He has more than 20 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rheumatology/autoimmune (HUMIRA), primary care (CELEBREX), orthopedic, diabetes (BYETTA), anti-infectives and cardiovascular spaces. This includes 10 product launches in roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott Immunology (now AbbVie), and Amylin Pharmaceuticals. Most recently, George served as president and chief executive officer of a privately held technology company.

Close Drawer

Vikram joined Horizon Pharma in July 2014 as group vice president and general manager, specialty business unit and has been in his current position since February 2017. Prior to joining Horizon, Vikram was with Fresenius Kabi, a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, where he served as vice president of the therapeutics and cell therapy business, with a focus on sales, marketing and clinical implementation. He also held various positions in business development, corporate strategy and strategic marketing within Fenwal Inc., a private equity owned global medical device company, that was acquired by Fresenius Kabi.

Vikram brings more than 15 years of cross functional expertise across a multitude of industries, including medical devices, management consulting, semiconductors and cellular telecommunications.

Vikram has a Master of Business Administration from the Kellogg School of Management at Northwestern University, a master’s degree in electrical engineering from Case Western Reserve University and a bachelor’s degree in electrical engineering from University of Bombay, India.

Close Drawer

David joined Horizon Pharma in September 2014 as executive vice president, managing director, Ireland and was appointed company secretary in November 2014. Prior to joining Horizon Pharma, he served as chief financial officer for Vidara Therapeutics, and was previously chief financial officer of AGI Therapeutics. He also served as senior vice president of Warner Chilcott (formerly Galen), a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company’s successful IPO on NASDAQ. In addition, David has held roles with Elan Corporation and KPMG.

David holds a bachelor’s degree in economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).

Close Drawer

Geoff joined Horizon Pharma and brings more than two decades of global healthcare communications experience including media relations, issues management, internal communications, corporate and product communications and executive visibility. Prior to joining Horizon Pharma, Geoff served senior vice president at Edelman Public Relations and as part of its National Health Media Team he led media strategy and execution for a large portfolio of pharmaceutical, biotech and medical device clients. He was responsible for developing and maintaining media relationships, as well as implementing media strategies to support regulatory and product milestones, data publication and global medical meetings.

Previously, Geoff was group director of the media practice at WCG, a W20 Group company, where he provided product and corporate communications counsel and handled ongoing media relations for a broad range of healthcare clients. Before WCG, he held a similar role at GCI Group.

Prior to joining GCI, Geoff served as a public affairs manager in the Pharmaceutical Products Division at Abbott (now AbbVie), where he led internal and external communications programs for the immunology, neuroscience and oncology franchises.

Geoff received a Bachelor of Arts in English from Lake Forest College in Lake Forest, Ill.

Close Drawer

Tim joined Horizon Pharma in June 2008 as president and chief executive officer and has served as chairman of our board of directors since 2010. Prior to joining Horizon Pharma plc, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Tim served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Tim served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth.

Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, Pa.. He serves as chairman of the board of Egalet Corporation (NASDAQ: EGLT) and the Illinois Biotechnology Innovation Organization (iBIO) and sits on the board of directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is also a member of the Illinois Innovation Council.

Close Drawer

Michael has served on ther board of directors since September 2011 and as lead independent director of the company since August 2012. He is executive chairman of Amplyx Pharmaceuticals, Inc., chairman and chief executive officer of Reneo Pharmaceuticals, Inc. and a venture partner at Pappas Ventures. Michael most recently served as president and chief executive officer at Lumena Pharmaceuticals, which was acquired by Shire plc in June 2014. He has more than 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc. For approximately 20 years, Michael also serves on the board of directors of BioMarin Pharmaceutical Inc., Mirati Therapeutics, Inc., Amplyx Pharmaceuticals, Inc., Balance Therapeutics, Inc. and Biothera Pharmaceuticals, Inc.

Michael received a Bachelor of Science in Chemistry from the University of Nottingham in the United Kingdom.

Close Drawer

Liam joined the board of directors in September 2014. Liam is a Chartered Director and Chartered Accountant, and was elected to the position of President of the Institute of Directors of Ireland in May 2013. In February 2015, he was appointed to the board of directors of Malin Corporation plc, a newly established Irish-based global life sciences company. Most recently, he was executive vice president and company secretary of Elan Corporation plc and served in that role from December 2001 until the merger of Elan with Perrigo in December 2013. He was previously an executive director of Elan between 2003 and 2007, having joined the organization as financial controller in 1994. He is also a former president of the Financial Executives’ Association of Ireland.

Liam graduated with a degree in commerce from the University College Dublin.

Close Drawer

Dr. Himawan has served on the board of directors since July 2007. In 1999, he joined Essex Woodlands Health Ventures, L.P., a venture capital firm, where he now serves as a managing director. He also serves on the boards of directors of Catalyst Biosciences, Inc., MediciNova, Inc. and Light Sciences Oncology, Inc. Dr. Himawan co-founded Seed-One Ventures, a venture capital firm, where from 1996 to 1999 he served as a managing director. From 1983 to 1996, Dr. Himawan was a scientist in academic and industrial settings.

Dr. Himawan received his Bachelor of Science in Biology from the Massachusetts Institute of Technology and his doctorate in biological chemistry and molecular pharmacology from Harvard University.

Close Drawer

Ron has served on the board of directors since September 2011. He is currently the chief financial officer of BioQ Pharma, Inc., a private specialty pharmaceutical company. Prior to that, Ron held senior positions at a number of biopharmaceutical companies, including chief financial officer at Sagent Pharmaceuticals, Inc. and NeoPharm, Inc. and corporate controller and interim chief financial officer at Abraxis BioScience, Inc. (formerly American Pharmaceutical Partners, Inc.). In addition, he previously served as corporate controller for Applied Power, Inc. and R.P. Scherer Corporation and held multiple finance positions at Kmart Corporation.

Ron received a Bachelor of Science in Accounting from Michigan State University and a master’s degree in finance from Walsh College.

Close Drawer

Gino has served on the board of directors since March 2012. He currently serves as the chairman of the board of directors of AMAG Pharmaceuticals, Inc. and is onthe board of directors of Intercept Pharmaceuticals and Collegium Pharmaceuticals, and is retired from a distinguished career with Eli Lilly and Company that spanned nearly three decades. Gino previously served on the board of directors for Sorin SpA from 2012 to 2015, when it was acquired by LivaNova plc. He capped his career at Lilly as a member of the company’s executive committee and as the senior vice president of corporate strategy and business development.

Gino holds a degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the University of Rochester.

Close Drawer

Tom has served on the board of directors since April 2014. In his most recent role, he was director, president and chief executive officer of Human Genome Sciences (HGS) from 2004 to 2012 when HGS was acquired by GlaxoSmithKline. Before leading HGS, Tom spent nearly 20 years in senior roles at Abbott and its affiliates in the United States and Asia, most recently serving as the president of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc. During his tenure, he led the growth of TAP from approximately $2 billion to more than $4 billion in annual revenue. Tom began his career in 1974 with Arthur Andersen & Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the United States, Europe and Japan.

Tom holds a bachelor’s degree from the College of William & Mary, and a Master of Business Administration from the University of Chicago Graduate School of Business. Currently, he is the chairman of the board of directors of Vanda Pharmaceuticals, Inc. He is also a member of the board of directors of the Biotechnology Innovation Organization (BIO) and a member of the board of visitors of the College of William & Mary.

Close Drawer

Pascale was appointed to the board in August 2017. She brings more than two decades of global healthcare management experience to the board and most recently served as executive vice president, global diabetes and cardiovascular at Sanofi. During her tenure with the company, she launched multiple medicines across three continents and strengthened the pipeline through licensing and partnerships. 

Prior to joining Sanofi, Pascale served more than 17 years at GE Healthcare where, in her final role as president and chief executive officer of its medical diagnostics business, she ran a $2 billion integrated pharmaceutical organization that encompassed research and development through commercial.
 
Pascale received her Master of Business Administration in Economics and Marketing from INSEAD and her Master of Science in Biochemistry from INSA Lyon. She currently serves on the board of directors for Fresenius Medical Care AG & Co. KGaA, a world leader in dialysis, Savencia SA, a food and dairy company; and Regulus Therapeutics, a biotechnology company focused on the discovery and development of microRNA therapeutics.

Close Drawer

Dr. Shannon was appointed to the board in August 2017. He most recently served as the chief medical officer of GlaxoSmithKline (GSK), where he was responsible for matters of patient safety, general medical governance, medical ethics and integrity, medical information as well as investigations involving human subjects relating to any GSK medicine in development or on the market.

Previously, Dr. Shannon spent more than a decade with Novartis. In his last role with the company, as global head of pharma development, he was responsible for all of Novartis’s development activities, from pre-clinical through Phase 4 and oversaw an annual development budget of approximately $4 billion.

Dr. Shannon received his science and medical degrees from Queen’s University in Belfast, Northern Ireland. He serves on the board of directors for MannKind Corporation, a biopharmaceutical company focused on treatments for diabetes; ProQR Therapeutics, a developer of RNA-based therapeutics; Immodulon Therapeutics, a biopharmaceutical company developing novel therapies using mycobacterial agents and MyTomorrows, a health-based platform that collaborates with drug developers to provide early access to treatments for patients who have exhausted all other options.

Close Drawer